Highnoon Laboratories Limited

HINOON

PK0070701013

Pharmaceuticals

End-of-day quote Pakistan S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
577.4 ^PKR	+3.93%		+9.16%	+14.44%

Apr. 09	Highnoon Laboratories Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Highnoon Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Highnoon Laboratories Limited Recommends Final Cash Dividend for the Year Ended December 31, 2020

March 25, 2021 at 07:13 am EDT

The board of directors of Highnoon Laboratories Limited has recommended final cash dividend for the year ended December 31, 2020, at the rate of 150% which is PKR 15 per share.

Latest news about Highnoon Laboratories Limited

Highnoon Laboratories Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 09	CI
Highnoon Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-29	CI
Highnoon Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-30	CI
Highnoon Laboratories Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-01	CI
Highnoon Laboratories Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-14	CI
Highnoon Laboratories Limited Announces Director Changes, Effective February 24, 2023	23-02-23	CI
Highnoon Laboratories Limited Announces Executive Changes	22-11-23	CI
Highnoon Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-30	CI
Highnoon Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-25	CI
Highnoon Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-10-22	CI
Highnoon Laboratories Limited Appoints Adeel Abbas Haider as Chief Executive Officer	21-09-09	CI
Highnoon Laboratories Limited Appoints Tauseef Ahmad Khan as Chairman	21-09-09	CI
Highnoon Laboratories Limited Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-12	CI
Highnoon Laboratories Limited Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-29	CI
Highnoon Laboratories Limited Recommends Final Cash Dividend for the Year Ended December 31, 2020	21-03-25	CI
Highnoon Laboratories Limited Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-25	CI
Highnoon Laboratories Limited Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-10-26	CI
Highnoon Laboratories Limited Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-24	CI
Highnoon Laboratories Limited Reports Earnings Results for the First Quarter Ended March 31, 2020	20-04-30	CI
Creso Pharma Limited Announces a Collaboration with Highnoon Laboratories Limited and Route2 Health Limited	20-04-13	CI
Highnoon Laboratories Limited Recommends Final Cash Dividend for the Year Ended December 31, 2019	20-03-31	CI
Highnoon Laboratories Limited Reports Earnings Results for the Full Year Ended December 31, 2019	20-03-31	CI
Highnoon Laboratories Limited Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-10-29	CI
Highnoon Laboratories Limited Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-26	CI
Highnoon Laboratories Limited Reports Earnings Results for the First Quarter Ended March 31, 2019	19-04-30	CI

Chart Highnoon Laboratories Limited

Duration

Period

More charts

Highnoon Laboratories Limited is a Pakistan-based company that is engaged in the manufacturing, importing, selling and marketing of pharmaceutical and allied consumer products. The Company's product categories include cardiology, metabolic, gastroenterology, musculoskeletal, anti-infective, obstetrics and gynecology, pediatrics, allergy, respiratory, and urology. Its cardiology products include Somno, Hitica, Apiban, Pidogrel-AP, Blokium DIU, Epliron, Sacuvia, Ivaset, Rivaro, Valforge and Herbesser. Its metabolic products include Xormet XR, MetFormin HCI, Diajard-MXR, Diajard-M and Diajard. The Company's gastroenterology products include Liv 52, Rabecid and Racedo. Its musculoskeletal products include Flexa Plus, Airtal ER and Tamadol. The Company's pediatric products include Bonisan, Cogniza, Flu Ace, Prospan and Tres Orix Forte. Its allergy products include Leviva and Kestine. Its Respiratory products include Combivair Forte, Sprahaler Respules, Foracort HFA Inhaler and Rotaflo.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HIGHNOON LABORATORIES LIMITED	+14.44%	110M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B